Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
01 Novembre 2022 - 12:00PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that Chen Schor, President
and Chief Executive Officer, will present at the 2022 Jefferies
London Healthcare Conference being held from November 15-17, 2022
in London.
Details of the event are as follows:
Date: Tuesday, November 15, 2022 Time: 7:25 a.m. GMT
The live audio webcast of the presentation can be accessed on
the Investors section of Adicet Bio’s website at
http://www.adicetbio.com. An archived replay will be available for
30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and adaptors (CAds), to enhance selective tumor targeting and
facilitate innate and adaptive anti-tumor immune response for
durable activity in patients. For more information, please visit
our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221101005354/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Lug 2023 a Lug 2024